• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
HIV Vaccine Market Opportunity & Clinical Pipeline Analysis - Product Image

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

  • ID: 2771349
  • March 2014
  • 330 Pages
  • Kuick Research

FEATURED COMPANIES

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • GenVec
  • GeoVax
  • Glaxo Smithkline
  • MORE

Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV.

Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.

HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries.

It has been observed that almost nine out of every ten HIV infections are being diagnosed READ MORE >

FEATURED COMPANIES

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • GenVec
  • GeoVax
  • Glaxo Smithkline
  • MORE

1. Introduction to HIV Vaccine & Mechanism
1.1 Introduction
1.2 The Mechanics of HIV Vaccines

2. HIV Vaccine: Prevention & Cure
2.1 Prevention
2.2 Cure & Access to Antiretroviral Therapy

3. Why Need For HIV Vaccines?

4. Global HIV Vaccine Market Outlook
4.1 HIV Incidence Scenario
4.2 Market Overview
4.3 Clinical Trial Analysis

5. Research & Development Funding Scenario for HIV Vaccine

6. HIV Vaccine Market Dynamics
6.1 Favorable Market Drivers
6.2 Challenges to be Resolved
6.3 Future Growth Opportunity

7. FDA Regulatory Framework for Development of HIV Vaccine
7.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
7.2 Guidance for Submitting HIV Resistance Data
7.3 HIV Resistance Testing in Antiretroviral Drug Development

8. HIV Vaccine Clinical Trial by Phase & Country
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase I
8.5 Phase I/II
8.6 Phase II
8.7 Phase III

9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended

10. Competitive Landscape
10.1 Antigen Express
10.2 Bionor Pharma
10.3 FIT Biotech
10.4 GeoVax
10.5 GenVec
10.6 Glaxo Smithkline
10.7 Immune Response BioPharma
10.8 Inovio Pharmaceuticals
10.9 Novartis
10.10 Sanofi Pasteur

List Of Tables and Figures:

Table 5-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 6-1: HIV Vaccine Impact Analysis on Incidence & Deaths

Figure 1-1: Vaccine Research Process
Figure 4-1: People Living With HIV Infection (Million), 2009-2014
Figure 4-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 4-3: People Living With HIV Infection by Region (%), 2012
Figure 4-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
Figure 4-5: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2018
Figure 4-6: HIV Vaccines in Clinical Trial by Phase (%), 2014
Figure 4-7: Number of HIV Vaccines in Clinical Trial by Phase, 2014
Figure 4-8: Suspended & Discontinued HIV Vaccines in Clinical Trial (%), 2014
Figure 4-9: Number of Suspended & Discontinued HIV Vaccines in Clinical Trial, 2014
Figure 4-10: Discontinued HIV Vaccines in Clinical Trial by Phase (%), 2014
Figure 4-11: Number of Discontinued HIV Vaccines in Clinical Trial by Phase, 2014
Figure 4-12: HIV Vaccines in Clinical Trial by Phase Where No Development Reported (%), 2014
Figure 4-13: Number of HIV Vaccines in Clinical Trial by Phase Where No Development Reported, 2014
Figure 5-1: Global HIV Vaccines R&D Funding (US$ Million), 2005–2012
Figure 5-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 5-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012

- Antigen Express
- Bionor Pharma
- FIT Biotech
- GenVec
- GeoVax
- Glaxo Smithkline
- Immune Response BioPharma
- Inovio Pharmaceuticals
- Novartis
- Sanofi Pasteur

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos